Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.314
Sell
RSI(14)
38.654
Neutral
STOCH(KDJ)(9,3,3)
17.325
Oversold
ATR(14)
0.697
Low Volatility
CCI(14)
-117.900
Sell
Williams %R
87.543
Oversold
TRIX(12,20)
-0.503
Sell
StochRSI(14)
6.950
Sell
DarioHealth Corp
DRIO9.950USD
+0.150+1.53%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
67.34MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of DarioHealth Corp
Currency: USD Updated: 2026-02-06Key Insights
DarioHealth Corp's fundamentals are relatively very healthy, with industry-average ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 108 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 18.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
DarioHealth Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative-
DarioHealth Corp Highlights
StrengthsRisks
DarioHealth Corp. is a global digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by data analytics, software, and personalized coaching. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management.
Growing
The company is in a growing phase, with the latest annual income totaling USD 27.04M.
Fairly Valued
The company’s latest PE is -0.90, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 795.75K shares, increasing 0.01% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 99.30K shares of this stock.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
18.000
Target Price
+77.69%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of DarioHealth Corp is 5.97, ranking 178 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 5.01M, representing a year-over-year decrease of 32.55%, while its net profit experienced a year-over-year decrease of 36.49%.
Score
Financials
8.10
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.16
Operational Efficiency
2.83
Growth Potential
4.67
Shareholder Returns
7.07
DarioHealth Corp's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of DarioHealth Corp is 7.51, ranking 78 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.90, which is -96.97% below the recent high of -0.03 and -156.28% above the recent low of -2.30.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 108/205
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of DarioHealth Corp is 8.00, ranking 60 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 18.50, with a high of 25.00 and a low of 11.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
18.000
Target Price
+77.69%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
114
Total
6
Median
9
Average
Company name
Ratings
Analysts
DarioHealth Corp
DRIO
4
Stryker Corp
SYK
32
Abbott Laboratories
ABT
31
Medtronic PLC
MDT
31
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of DarioHealth Corp is 6.76, ranking 87 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 11.88 and the support level at 8.80, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
10.384
Sell
MA10
10.567
Sell
MA20
11.281
Sell
MA50
11.549
Sell
MA100
12.427
Sell
MA200
12.511
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of DarioHealth Corp is 3.00, ranking 134 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 7.67%, representing a quarter-over-quarter decrease of 53.79%. The largest institutional shareholder is The Vanguard, holding a total of 99.30K shares, representing 1.47% of shares outstanding, with 67.94% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Tasso Partners, LLC
Kallman (Craig)
Nantahala Capital Management, LLC
Solid Financial LLC
Raphael (Erez)
Stern (Adam K.)
Franco-Yehuda (Chen)
Avenue Capital Group
Geode Capital Management, L.L.C.
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of DarioHealth Corp is 1.97, ranking 169 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.12. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. DarioHealth Corp’s latest ESG disclosure is at an average level in the Healthcare Equipment & Supplies industry, showing no material impact on overall risk.
Score
Beta vs S&P 500 index
1.11
VaR
+8.35%
240-Day Maximum Drawdown
+62.38%
240-Day Volatility
+108.17%
Return
Best Daily Return
60 days
+19.30%
120 days
+42.75%
5 years
+79.54%
Worst Daily Return
60 days
-15.57%
120 days
-16.41%
5 years
-41.25%
Sharpe Ratio
60 days
-0.41
120 days
+0.81
5 years
-0.30
Risk Assessment
Maximum Drawdown
240 days
+62.38%
3 years
+92.88%
5 years
+95.04%
Return-to-Drawdown Ratio
240 days
-0.45
3 years
-0.32
5 years
-0.11
Skewness
240 days
+1.98
3 years
+2.46
5 years
+2.28
Volatility
Realised Volatility
240 days
+108.17%
5 years
+172.85%
Standardised True Range
240 days
+11.10%
5 years
+22.71%
Downside Risk-Adjusted Return
120 days
+185.18%
240 days
+185.18%
Maximum Daily Upside Volatility
60 days
+90.44%
Maximum Daily Downside Volatility
60 days
+71.65%
Liquidity
Average Turnover Rate
60 days
+0.46%
120 days
+0.51%
5 years
--
Turnover Deviation
20 days
-19.54%
60 days
-33.18%
120 days
-24.60%
Peer Comparison
Healthcare Equipment & Supplies
DarioHealth Corp
DRIO
6.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
COR
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Becton Dickinson and Co
BDX
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Align Technology Inc
ALGN
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
